Selective acceleration
Two phases shrink by 100x; two remain fixed.
Can ten years 3,652.5 → 10 fit inside ten days?
Make every phase and speedup explicit. The protected floor decides whether selective acceleration can reach the claim.
Edit the phase docket
Illustrative equal split. Not empirical.
DAYS
Will protected phases block it?
PHASEBASELINESPEEDUPPROTECT
Bundled arithmetic fixture ready: four equal phases totaling ten years.
CLAIM UNDER TESTTen years to ten days requires more than a fast first phase. Analyze the whole docket.
CLINICAL TIMELINE BOTTLENECK TEST / MODEL COMPLETE
TARGET BLOCKED BY PROTECTED PHASES
MODELED TOTAL1,844.5125 DAYS
OVERALL SPEEDUP1.9802x
PROTECTED FLOOR1,826.2500 DAYS
UNIFORM REQUIREMENT365.2500x
The fast half cannot outrun the fixed half.
Controlled counterfactual
Only an assumption that moves every phase can cross the ten-day line in this fixture.
LOCAL VS TOTAL SPEEDUP
A phase multiplier acts only on that phase. The schedule speedup comes from the sum that remains.
Use the labels. Do not borrow certainty.
One transparent sum
Each phase contributes baseline days divided by its own multiplier. Protected phases stay at 1x and define the infinite-acceleration floor.
FDA labels, not FDA durations
The official pages support the process labels and distinguish preclinical from research in people. The equal 913.125-day values are only this site's arithmetic fixture.
No medical feasibility claim
Schedule compression cannot prove biology, safety, efficacy, evidence quality, recruitment, manufacturing readiness, regulatory approval, or superintelligence.
FDA: The Drug Development Process
Used only for the sequence of Discovery, Preclinical, Clinical Research, and Review.
FDA: Step 3 Clinical Research
Supports that clinical research means studies in people and contains distinct phases.